Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
Domingo A. Pascual‐Figal, Antoni Bayés‐Genís, Paola Beltrán-Troncoso, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential
Thomas G. Martin, Miranda A. Juarros, Leslie A. Leinwand
Nature Reviews Cardiology (2023) Vol. 20, Iss. 5, pp. 347-363
Open Access | Times Cited: 79
Neprilysin Inhibitors in Heart Failure
Biykem Bozkurt, Ajith Nair, Arunima Misra, et al.
JACC Basic to Translational Science (2022) Vol. 8, Iss. 1, pp. 88-105
Open Access | Times Cited: 63
Neurohumoral Activation in Heart Failure
Antonis A. Manolis, Theodora A. Manolis, Antonis S. Manolis
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15472-15472
Open Access | Times Cited: 32
Potential renoprotective effects and possible underlying mechanisms of angiotensin receptor-neprilysin inhibitors in cardiorenal syndrome
Md. Moshiur Rahman, Asadur Rahman, Akira Nishiyama
Frontiers in Medicine (2025) Vol. 11
Open Access | Times Cited: 1
Efficacy and safety of angiotensin receptor–neprilysin inhibition in heart failure patients with end‐stage kidney disease on maintenance dialysis: A systematic review and meta‐analysis
Nguyễn Việt Dũng, Thanh Ngoc Le, Binh Quang Truong, et al.
European Journal of Heart Failure (2024)
Open Access | Times Cited: 8
Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
Nor Hidayah Mustafa, Juriyati Jalil, Satirah Zainalabidin, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 26
Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists
Jamshed Dalal, Praveen Chandra, Saumitra Ray, et al.
Cardiology and Therapy (2023) Vol. 12, Iss. 3, pp. 445-471
Open Access | Times Cited: 13
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
Safia Chatur, Brian Claggett, Orly Vardeny, et al.
European Journal of Heart Failure (2022) Vol. 25, Iss. 1, pp. 87-94
Open Access | Times Cited: 19
Angiotensin-Converting Enzyme and Heart Failure
Sara Álvarez-Zaballos, Manuel Martínez‐Sellés
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 7
Open Access | Times Cited: 11
Emerging Role of Natriuretic Peptides in Diabetes Care: A Brief Review of Pertinent Recent Literature
Dipti Tiwari, Tar Choon Aw
Diagnostics (2024) Vol. 14, Iss. 19, pp. 2251-2251
Open Access | Times Cited: 3
The Angiotensin Receptor–Neprilysin Inhibitor is Related to Lower Post-transplant Use of Extracorporeal Membrane Oxygenation
Yuan Li, Zhaohua Yang, Wenrui Ma, et al.
The Heart Surgery Forum (2025) Vol. 28, Iss. 1, pp. E010-E018
Open Access
Effects of sacubitril/valsartan on cardiac remodeling in heart failure with reduced ejection fraction: An integrated study of molecular biomarkers and imaging techniques
Ainhoa Robles Mezcua, James L. Januzzi, Francisco Javier Pavón, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117874-117874
Closed Access
Angiography-derived index of microcirculatory resistance as a novel tool to assess coronary microvascular dysfunction in patients with diabetic cardiomyopathy
Zhan Gao, Xue Hua Qian, Jing Ke, et al.
International Journal of Cardiology (2025) Vol. 431, pp. 133220-133220
Open Access
Design and development of chromene-3-carboxylate derivatives as antidiabetic agents: Exploring the antidiabetic potential via dual inhibition of Angiotensin II Type 1 Receptor and Neprilysin enzyme
Shikha Thakur, Sandhya Chahal, Madhav S. Jadhav, et al.
European Journal of Medicinal Chemistry (2025) Vol. 293, pp. 117705-117705
Closed Access
The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials
Jinquan Gao, Xin Zhang, Mengzhuo Xu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis
Jianbin Qin, Weijian Wang, Ping Wei, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 13
A comprehensive review of the literature on CD10: its function, clinical application, and prospects
Shudong Wang, Yinghui Xiao, Xingna An, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Safety and Efficacy of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: Multicentre Retrospective Study on Echocardiographic Parameters and Biomarkers of Heart Congestion
Ilaria Battistoni, Giulia Pongetti, Elena Falchetti, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 12, pp. 3522-3522
Open Access | Times Cited: 2
Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy
Peter Galis, Linda Bartosova, Veronika Farkašová, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 2
Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction
Michele Correale, Pietro Mazzeo, Lucia Tricarico, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 7, pp. 567-579
Closed Access | Times Cited: 10
Angiotensin receptor-neprilysin inhibitor therapy and recurrence of atrial fibrillation after radiofrequency catheter ablation: A propensity-matched cohort study
Youzheng Dong, Shucai Xiao, Jinwu He, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 9
Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation
Youzheng Dong, Zhenyu Zhai, Jihong Wang, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Long-Term Treatment With Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction ― Open-Label Extension of the PARALLEL-HF Study ―
Hiroyuki Tsutsui, Shin‐ichi Momomura, Yoshihiko Saito, et al.
Circulation Journal (2023) Vol. 88, Iss. 1, pp. 43-52
Open Access | Times Cited: 5
The Pathophysiology and New Advancements in the Pharmacologic and Exercise-Based Management of Heart Failure With Reduced Ejection Fraction: A Narrative Review
Snaiha I Narayan, Giselle V Terre, Rutvi Amin, et al.
Cureus (2023)
Open Access | Times Cited: 5
Sacubitril/Valsartan in Heart Failure Hospitalization: Two Pills a Day to Keep Hospitalizations Away?
Navya Sakhamuri, Sreekartthik Athiyaman, Bhawna Randhi, et al.
Cureus (2023)
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top